阿布昔替尼治疗中、重度特应性皮炎的研究进展  

Research progress on abrocitinib in the treatment of moderate and severe atopic dermatitis

作　　者：朱旭 吴文中[1] ZHU Xu;WU Wenzhong(Second People's Hospital of Shenzhen,First Hospital Affiliated to Shenzhen University,Shenzhen 518035,China)

机构地区：[1]深圳市第二人民医院深圳大学第一附属医院,广东深圳518035

出　　处：《皮肤性病诊疗学杂志》2023年第4期372-376,共5页Journal of Diagnosis and Therapy on Dermato-venereology

摘　　要：特应性皮炎(AD)是一种以瘙痒性皮损为主要特征的炎症性皮肤病,传统治疗对中、重度AD疗效不佳。AD具有复杂的病理生理机制。JAK-STAT通路在AD的发病机制中起着重要作用。阿布昔替尼是一种具有高度选择性的口服Janus激酶1(JAK1)抑制剂,通过JAK-STAT信号转导通路及激活通路可抑制参与AD发病的细胞因子IL-4、IL-13、和IL-31等的表达,最终阻断AD的发生、发展。阿布昔替尼在治疗难治性中、重度AD中表现出良好的有效性、耐受性及安全性。本文就其药理机制、临床疗效、安全性及实际应用进行综述。Atopic dermatitis(AD)is an inflammatory skin disease characterized by pruritus.The efficacy of traditional treatment for moderate and severe AD is not satisfactory.AD has complex and multi-factor pathophysiological mechanisms.JAK-STAT pathway plays an important role in the pathogenesis of AD.Abrocitinib is a highly selective oral inhibitor of janus kinase 1(JAK1),which can inhibit JAK-STAT signal transduction and activation pathways,resulting in down-regulation of the expression of IL-4,IL-13 and IL-31,which all are involved in the pathogenesis of AD,and ultimately blocks the occurrence and the development of AD.Abrocitinib has shown a good efficacy,tolerability and safety in the treatment of refractory moderate to severe AD.This article reviews the pharmacological mechanisms,clinical efficacy,safety and clinical applications of abrocitinib.

关 键 词：阿布昔替尼 JAK1抑制剂 特应性皮炎 

分 类 号：R758.2[医药卫生—皮肤病学与性病学]